Deals
-
Takeda pays $400M to buy into Hutchmed’s colorectal cancer drug
The deal is the second big licensing deal Takeda has signed in as many months and gives the company rights to a drug Hutchmed began submitting to U.S. regulators in December.
By Christopher Newman • Jan. 23, 2023 -
3 biotech executives on the year ahead: deals, drug pricing and the down market
“What we’re experiencing now is the aftershock of the party that went on for the last three years,” said Ovid CEO Jeremy Levin in a BioPharma Dive panel that included former Sage head Jeff Jonas and biotech entrepreneur Greg Verdine.
By Jacob Bell • Jan. 19, 2023 -
Explore the Trendline➔
Brian Tucker / BioPharma DiveTrendlineBiotech dealmaking
Acquisitions of biotech companies have picked up in recent quarters, suggesting depressed valuations may be facilitating deal conversations. Read this trendline for a look at the factors impacting M&A.
By BioPharma Dive staff -
Editas, in next restructuring step, to sell cell therapy work to Shoreline
Shoreline will acquire a preclinical NK cell therapy Editas has been developing, as well as a license to use the CRISPR biotech’s gene editing technology.
By Ned Pagliarulo • Jan. 19, 2023 -
Sun Pharma to buy Concert, pick up experimental hair loss drug
Sun intends to submit the drug, called deuruxolitinib, for U.S. approval in the first half of this year, following in the footsteps of similar therapies from Pfizer and partners Eli Lilly and Incyte.
By Christopher Newman • Jan. 19, 2023 -
Leap Therapeutics to buy Flame Biosciences in all-stock deal
The deal gives Leap several early-stage drug candidates, including an antibody targeting the protein Claudin 18.2, which has lately drawn several other biotech companies’ interest.
By Delilah Alvarado • Jan. 17, 2023 -
JPM23: Vaccine developers as dealmakers, Gilead’s trial tea leaves and building platform companies
Arrakis CEO Michael Gilman discussed platform companies’ central challenge, while Moderna’s Stéphane Bancel and Pfizer’s Albert Bourla hinted at greater dealmaking to come for their companies.
By Jacob Bell , Ben Fidler , Jonathan Gardner • Jan. 10, 2023 -
Trio of biotech buyouts jumpstarts J.P. Morgan healthcare meeting
AstraZeneca is acquiring CinCor Pharma, while Ipsen and Chiesi announced deals to buy rare disease drugmakers Albireo and Amryt Pharma, respectively.
By Ned Pagliarulo • Jan. 9, 2023 -
Ensoma buys a startup to advance ‘in vivo’ cell therapy work
The Takeda-backed biotech revealed it’s raised $85 million in new funding alongside announcing the acquisition of gene editing startup Twelve Bio.
By Delilah Alvarado • Jan. 6, 2023 -
Kenvue, J&J’s consumer health unit, files for an IPO in step toward split
The IPO, which one estimate said could raise as much as $5 billion, is likely to be one of the largest new stock offerings in recent years.
By Delilah Alvarado • Jan. 5, 2023 -
Moderna, becoming a buyer, acquires a synthetic biology specialist
The biotech said its first acquisition, an $85 million purchase of Japanese company OriCiro Genomics, will hand it better tools to make a key building block of messenger RNA.
By Kristin Jensen • Jan. 4, 2023 -
Lilly pays $75M to widen RNA editing deal with ProQR
The expanded deal triples the amount of money the biotech could eventually receive from Lilly and adds several more neurological disease drug targets.
By Christopher Newman • Dec. 22, 2022 -
Jazz pays Zymeworks $325M for HER2 drug rights after positive data
Two months after signing a deal with Zymeworks, Jazz exercised an option for the drug after it showed potential in treating biliary tract cancer.
By Christopher Newman • Dec. 21, 2022 -
Gilead buys Tmunity, cozying up to a CAR-T pioneer
Tmunity, a private biotech co-founded by cell therapy researcher Carl June, offers Gilead a slate of experimental programs, a technology platform and an alliance with the University of Pennsylvania.
By Jacob Bell • Dec. 20, 2022 -
Roche, Biogen sign royalty deal for late-stage lymphoma drug
Roche will pay royalties to Biogen on glofitimab, part of a long-standing collaboration between the two companies that’s resulted in Rituxan and Ocrevus.
By Jonathan Gardner • Updated Dec. 26, 2022 -
Lilly partners with Sosei to develop drugs aimed at a key family of proteins
The pharma will pay Sosei $37 million upfront to discover new candidates for diabetes and metabolic diseases that target G protein-coupled receptors.
By Christopher Newman • Dec. 16, 2022 -
Q&A // Emerging biotech
Nimbus CEO Jeb Keiper on negotiating a $4B deal and building an unorthodox biotech startup
Days after inking one of the largest deals for an unapproved drug, the CEO spoke with BioPharma Dive about the company’s unusual origins and decision to remain private — for now.
By Ben Fidler • Dec. 16, 2022 -
GSK gives Wave a lift with genetic medicine deal
A four-year agreement between the companies comes with $170 million in cash and equity for Wave, which in recent years has dealt with clinical setbacks.
By Kristin Jensen • Dec. 14, 2022 -
Takeda to pay $4B for Nimbus’ TYK2 drug
In one of the largest single-asset deals in recent history, the Japanese pharma is acquiring a medicine Nimbus claims can top Bristol Myers’ recently approved psoriasis drug Sotyktu.
By Ben Fidler • Dec. 13, 2022 -
Amgen to buy Horizon in year’s biggest biotech deal
After outlasting rival suitors Sanofi and J&J in deal talks, Amgen agreed to a deal that values the Ireland-based maker of rare and inflammatory disease drugs at about $28 billion.
By Ned Pagliarulo • Updated Dec. 12, 2022 -
Gilead buys into multiple myeloma cell therapy with Arcellx deal
The company is paying Arcellx $225 million, on top of a $100 million equity investment, for rights to a CAR-T therapy that’s currently in mid-stage testing as a treatment for the blood cancer.
By Jacob Bell • Dec. 9, 2022 -
Vertex invests in a rare disease drug and its developer
The big biotech is paying Entrada Therapeutics $250 million upfront to grab rights to an experimental treatment for myotonic dystrophy type 1 in the latest bid to build its pipeline.
By Jacob Bell • Dec. 8, 2022 -
TherapeuticsMD to offload drugs to Australia’s Mayne after failed buyout
After a private equity takeover unraveled this summer, the women’s health company is selling its drug portfolio to Mayne Pharma in a $153 million deal.
By Delilah Alvarado • Dec. 5, 2022 -
J&J drops out of hunt for Horizon, leaving Sanofi and Amgen to bid
The two remaining suitors said they would make cash bids if they move forward with offers, for which they must declare “firm intent” by Jan. 10 under Irish takeover rules.
By Christopher Newman • Dec. 5, 2022 -
Pfizer, Roivant set up new company around inflammation drug
The drug is currently in mid-stage testing as a treatment for ulcerative colitis. If it continues to advance, it could be the first approved therapy aimed at a protein known as TL1A, a target multiple other companies are pursuing.
By Jacob Bell • Dec. 1, 2022 -
Large pharmas probe takeover of Horizon Therapeutics
The Dublin-headquartered drugmaker confirmed it is in "highly preliminary" talks with Amgen, J&J and Sanofi, although it cautioned no offer may ever materialize.
By Ned Pagliarulo • Updated Nov. 30, 2022